156 related articles for article (PubMed ID: 35878698)
1. Undergrowth Of First Toe In PiK3CA-Related Overgrowth Spectrum (PROS).
Triana P; Sarmiento MDC; Rodriguez-Laguna L; Martinez-Glez V; Lopez-Gutierrez JC
Ann Vasc Surg; 2023 Jan; 88():233-238. PubMed ID: 35878698
[TBL] [Abstract][Full Text] [Related]
2. Segmental undergrowth is associated with pathogenic variants in vascular malformation genes: A retrospective case-series study.
Martinez-Glez V; Rodriguez-Laguna L; Viana-Huete V; García Torrijos C; Hurtado B; Lapunzina P; Triana P; López-Gutiérrez JC
Clin Genet; 2022 Mar; 101(3):296-306. PubMed ID: 34850385
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
4. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
5. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
6. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
de Kock L; Cuillerier A; Gillespie M; Couse M; Hartley T; Mears W; Bernier FP; Chudley AE; Frosk P; Nikkel SM; Innes AM; Lauzon J; Thomas M; Guerin A; Armour CM; Weksberg R; Scott JN; Watkins D; Harvey S; Cytrynbaum C; ; Kernohan KD; Boycott KM
Am J Med Genet A; 2024 Mar; 194(3):e63466. PubMed ID: 37949664
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of the disorders of the Pik3ca-related overgrowth spectrum (Pros).
Reynolds G; Cardaropoli S; Carli D; Luca M; Gazzin A; Coppo P; La Selva R; Piglionica M; Bagnulo R; Turchiano A; Ranieri C; Resta N; Mussa A
Eur J Hum Genet; 2023 Nov; 31(11):1333-1336. PubMed ID: 37365400
[TBL] [Abstract][Full Text] [Related]
9. Novel features of PIK3CA-Related Overgrowth Spectrum: Lesson from an aborted fetus presenting a de novo constitutional PIK3CA mutation.
De Graer C; Marangoni M; Romnée S; Delaunoy M; Zaytouni S; D'Haene N; Désir J; Donner C
Eur J Med Genet; 2020 Apr; 63(4):103775. PubMed ID: 31568861
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Keppler-Noreuil KM; Lozier J; Oden N; Taneja A; Burton-Akright J; Sapp JC; Biesecker LG
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):571-581. PubMed ID: 31490637
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing.
Kuentz P; St-Onge J; Duffourd Y; Courcet JB; Carmignac V; Jouan T; Sorlin A; Abasq-Thomas C; Albuisson J; Amiel J; Amram D; Arpin S; Attie-Bitach T; Bahi-Buisson N; Barbarot S; Baujat G; Bessis D; Boccara O; Bonnière M; Boute O; Bursztejn AC; Chiaverini C; Cormier-Daire V; Coubes C; Delobel B; Edery P; Chehadeh SE; Francannet C; Geneviève D; Goldenberg A; Haye D; Isidor B; Jacquemont ML; Khau Van Kien P; Lacombe D; Martin L; Martinovic J; Maruani A; Mathieu-Dramard M; Mazereeuw-Hautier J; Michot C; Mignot C; Miquel J; Morice-Picard F; Petit F; Phan A; Rossi M; Touraine R; Verloes A; Vincent M; Vincent-Delorme C; Whalen S; Willems M; Marle N; Lehalle D; Thevenon J; Thauvin-Robinet C; Hadj-Rabia S; Faivre L; Vabres P; Rivière JB
Genet Med; 2017 Sep; 19(9):989-997. PubMed ID: 28151489
[TBL] [Abstract][Full Text] [Related]
13. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.
Morin G; Degrugillier-Chopinet C; Vincent M; Fraissenon A; Aubert H; Chapelle C; Hoguin C; Dubos F; Catteau B; Petit F; Mezel A; Domanski O; Herbreteau G; Alesandrini M; Boddaert N; Boutry N; Broissand C; Han TK; Branle F; Sarnacki S; Blanc T; Guibaud L; Canaud G
J Exp Med; 2022 Mar; 219(3):. PubMed ID: 35080595
[TBL] [Abstract][Full Text] [Related]
14.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
15. Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.
Tian W; Sun L; Zhang Q; Zhao J; Guo Y; Zhong W; Liu L; Meirelles K; Tang S; Zhang J; Huang Y; Yin Y; Zhang N; Zhao Z; Li Q; Wu N; Fang P; Chang F; Wu Z
Mol Genet Genomics; 2022 Mar; 297(2):387-396. PubMed ID: 35122151
[TBL] [Abstract][Full Text] [Related]
16. Kaposiform hemangioendothelioma further broadens the phenotype of PIK3CA-related overgrowth spectrum.
Carli D; Kalantari S; Manicone R; Coppo P; Francia di Celle P; La Selva R; Santoro F; Ranieri C; Cardaropoli S; Fagioli F; Ferrero GB; Resta N; Mussa A
Clin Genet; 2021 Nov; 100(5):624-627. PubMed ID: 34402524
[TBL] [Abstract][Full Text] [Related]
17. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G; Lopez Gutierrez JC; Irvine AD; Vabres P; Hansford JR; Ankrah N; Branle F; Papadimitriou A; Ridolfi A; O'Connell P; Turner S; Adams DM
Genet Med; 2023 Dec; 25(12):100969. PubMed ID: 37634128
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA vascular overgrowth syndromes: an update.
Hughes M; Hao M; Luu M
Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
[TBL] [Abstract][Full Text] [Related]
19. Complex vascular anomalies and tissue overgrowth of limbs associated with increased skin temperature and peripheral venous dilatation: parks weber syndrome or PROS?
Su LX; Sun Y; Wang Z; Wang D; Yang X; Zheng L; Wen M; Fan X; Cai R
Hereditas; 2022 Jan; 159(1):1. PubMed ID: 34980271
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
